Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory...

Abstract

CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed or refractory multiple myeloma with poor prognosis. Janssen Research & Development and Legend Biotech.

Keywords

Chimeric antigen receptorAntigenRefractory (planetary science)MedicineOpen labelMultiple myelomaReceptorImmunologyCellImmunotherapyCancer researchBiologyInternal medicineImmune systemClinical trial

MeSH Terms

AgedB-Cell Maturation AntigenFemaleHumansImmunotherapyAdoptiveMaleMiddle AgedMultiple MyelomaProgression-Free SurvivalReceptorsChimeric AntigenUnited States

Affiliated Institutions

Related Publications

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster , Michael Bishop , Constantine S. Tam +21 more

In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use o...

2018 New England Journal of Medicine 3775 citations

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

Shannon L. Maude , Theodore W. Laetsch , Jochen Buechner +32 more

In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients wit...

2018 New England Journal of Medicine 5232 citations

Cancer immunotherapy using checkpoint blockade

Antoni Ribas , Jedd D. Wolchok

The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses i...

2018 Science 6236 citations

The biologic importance of tumor‐infiltrating lymphocytes

F. Stephen Hodi , Glenn Dranoff

Detailed pathologic analysis has delineated a close association between intratumoral CD 8 + cytotoxic T cells and favorable clinical outcomes in diverse cancers. Conversely, the...

2010 Journal of Cutaneous Pathology 55 citations

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi , Steven O’Day , David F. McDermott +26 more

Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse eve...

2010 New England Journal of Medicine 14794 citations

Publication Info

Year: 2021
Type: article
Volume: 398
Issue: 10297
Pages: 314-324
Citations: 1466
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1466

OpenAlex

Influential

1332

CrossRef

Cite This

APA Style

                            
                                
                                    Jesús G. Berdeja, 
                                
                                    Deepu Madduri, 
                                
                                    Saad Z. Usmani
                                
                                et al.
                            
                            (2021). 
                            Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. 
                            The Lancet
                            , 398
                            (10297)
                            , 314-324.
                            https://doi.org/10.1016/s0140-6736(21)00933-8
                        

Identifiers

DOI: 10.1016/s0140-6736(21)00933-8
PMID: 34175021

Data Quality

Data completeness: 86%